



NDA 204781/S-001

SUPPLEMENT APPROVAL

Guerbet LLC
Attention: Alice Lorenzo, MJ, MBe, RAC
Compliance Officer, Head of North American
Regulatory and Quality
821 Alexander Road, Suite 204
Princeton, NJ 08540

Dear Ms. Lorenzo:

Please refer to your Supplemental New Drug Application (sNDA) dated and received on October 27, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Dotarem® (Gadoterate Meglumine) injection.

We acknowledge receipt of your amendments dated December 21, 2016, January 31, 2017, April 4, 2017, April 13, 2017, June 8, 2017, July 11, 2017, July 14, 2017, August 18, 2017, August 21, 2017, August 23, 2017, and August 25, 2017.

This Prior Approval supplemental new drug application provides for intravenous use of Dotarem with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package inserts, with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We note that you have fulfilled the pediatric study requirement for all relevant pediatric age groups for this application.

FULFILLMENT OF POSTMARKETING REQUIREMENT

We have received your submissions dated June 3, 2016, August 15, 2016, and October 27, 2016, containing the final report for the following postmarketing requirement listed in the March 20, 2013, approval letter. We also refer to our July 7, 2016 PREA non-compliance letter which requested a labeling supplement.

Study 2021-2: Examine patients 0-23 months of age who are referred for an MRI exam with contrast. A sufficient number of subjects will be studied to adequately characterize the pharmacokinetics of the product in this age group. At least 40 patients will be evaluated in this study, and the study must include a sufficient number of subjects to adequately support the safety and efficacy of Dotarem for central nervous system MRI.

We have reviewed your submission and conclude that the above requirement was fulfilled.

This completes all of your postmarketing requirements and postmarketing commitments acknowledged in our March 20, 2013, letter.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory

comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf>).

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>. Information and Instructions for completing the form can be found at <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Su-Lin Sun, PharmD, Senior Regulatory Project Manager by email su-lin.sun@fda.hhs.gov , or by phone (301)796-0036.

Sincerely,

{See appended electronic signature page}

Libero Marzella, M.D., Ph.D.
Director
Division of Medical Imaging Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling
Content of Labeling for Pharmacy Bulk Pack

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

LIBERO L MARZELLA
08/25/2017